학술논문
Auto-antibodies against type I IFNs in > 10% of critically ill COVID-19 patients: a prospective multicentre study
Document Type
article
Author
Romain Arrestier; Paul Bastard; Thibaut Belmondo; Guillaume Voiriot; Tomas Urbina; Charles-Edouard Luyt; Adrian Gervais; Lucy Bizien; Lauriane Segaux; Mariem Ben Ahmed; Raphaël Bellaïche; Taï Pham; Zakaria Ait-Hamou; Damien Roux; Raphael Clere-Jehl; Elie Azoulay; Stéphane Gaudry; Julien Mayaux; Nicolas Fage; Hafid Ait-Oufella; Elsa Moncomble; Mélodie Parfait; Karim Dorgham; Guy Gorochov; Armand Mekontso-Dessap; Florence Canoui-Poitrine; Jean-Laurent Casanova; Sophie Hue; Nicolas de Prost
Source
Annals of Intensive Care, Vol 12, Iss 1, Pp 1-11 (2022)
Subject
Language
English
ISSN
2110-5820
Abstract
Abstract Background Auto-antibodies (auto-Abs) neutralizing type I interferons (IFN) have been found in about 15% of critical cases COVID-19 pneumonia and less than 1% of mild or asymptomatic cases. Determining whether auto-Abs influence presentation and outcome of critically ill COVID-19 patients could lead to specific therapeutic interventions. Our objectives were to compare the severity at admission and the mortality of patients hospitalized for critical COVID-19 in ICU with versus without auto-Abs. Results We conducted a prospective multicentre cohort study including patients admitted in 11 intensive care units (ICUs) from Great Paris area hospitals with proven SARS-CoV-2 infection and acute respiratory failure. 925 critically ill COVID-19 patients were included. Auto-Abs neutralizing type I IFN-α2, β and/or ω were found in 96 patients (10.3%). Demographics and comorbidities did not differ between patients with versus without auto-Abs. At ICU admission, Auto-Abs positive patients required a higher FiO2 (100% (70–100) vs. 90% (60–100), p = 0.01), but were not different in other characteristics. Mortality at day 28 was not different between patients with and without auto-Abs (18.7 vs. 23.7%, p = 0.279). In multivariable analysis, 28-day mortality was associated with age (adjusted odds ratio (aOR) = 1.06 [1.04–1.08], p